Andromeda wins FDA orphan status for diabetes drug

[Northerner]

Andromeda Biotech Ltd. has obtained orphan drug status from the US Food and Drug Administration (FDA) for its DiaPep277 drug for the treatment of type 1 (juvenile onset) diabetes.
Andromeda is currently conducting a Phase III clinical trial of Diapep277, which can prevent the destruction of insulin secreting beta cells. The drug is designed to treat type 1 diabetes patients with residual insulin secreting cells in order to preserve their function.

Orphan drug status gives the company seven years marketing exclusivity in the US, tax breaks, assistance in registration, and in financing of clinical trials.

http://www.globes.co.il/serveen/globes/docview.asp?did=1000750938

I find this interesting, given that I appear to have recovered some beta-cell function four years after diagnosis - wonder if I've been an unwitting member of their trial? 😱 🙂

 

[trophywench]

I'm a bit dubious as to whether this is a real benefit?

I mean fine if it preserves a fully functioning complement of Beta cells. But say the insulin production was - or became - sporadic? You wouldn't know how much or whether to jab ....